The historical rank and industry rank for Catheter Precision's FCF Margin % or its related term are showing as below:
VTAK'
s FCF Margin % Range Over the Past 10 Years
Min: -161321.43 Med: -1626.26 Max: -35.07
Current: -811.01
During the past 10 years, the highest FCF Margin % of Catheter Precision was -35.07%. The lowest was -161321.43%. And the median was -1626.26%.
VTAK's FCF Margin % is ranked worse than 93.87% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs VTAK: -811.01
Catheter Precision FCF Margin % Related Terms
Catheter Precision FCF Margin % Historical Data
* Premium members only.
The historical data trend for Catheter Precision's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Catheter Precision's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catheter Precision FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Catheter Precision's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Catheter Precision's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catheter Precision (VTAK) has a FCF Margin % of -672.45% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Catheter Precision and its competitors. According to the industry distribution chart, Catheter Precision ranks #765 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 93.9%.
Is Catheter Precision's FCF Margin % too high?
Catheter Precision's current FCF Margin % is -672.45%. Based on the distribution chart, Catheter Precision ranks #765 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Catheter Precision has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Catheter Precision's FCF Margin % compare to VYCO and BJDX?
According to the Medical Devices & Instruments industry distribution chart, Catheter Precision ranks #765 out of 815 companies for FCF Margin %. This places Catheter Precision in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Catheter Precision and its competitors. Catheter Precision's current FCF Margin % is -672.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catheter Precision stock overvalued right now?
Based on GuruFocus' analysis, Catheter Precision (VTAK) is currently considered Possible Value Trap. The stock's GF Value™ is $1.72, compared to a current price of $1.19 — trading 30.8% below its estimated fair value. The current FCF Margin % is -672.45%. Catheter Precision's overall GF Score™ is 28/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Catheter Precision (VTAK), the current FCF Margin % is -672.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catheter Precision (VTAK) Overvalued in 2026?
Based on GuruFocus' analysis, Catheter Precision stock appears to be undervalued.
The current stock price of $1.19 is trading 30.8% below its estimated GF Value™ of $1.72.
GuruFocus considers Catheter Precision to be Possible Value Trap.
Key valuation signals for VTAK:
FCF Margin %: -672.45%
GF Value™: $1.72 vs. price of $1.19 (30.8% below fair value)
No single metric tells the full story. See the VTAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
28GF Score
Get the complete analysis for VTAK
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTAK has been successfully added to your 
